Position of the Transparency Council – Raxone (idebenone)
At its meeting on 19 May 2025, the Transparency Council adopted position No. 63/2025 on the appropriateness of granting approval for reimbursement of the medicinal product Raxone (idebenone) for the indication of Leber’s hereditary optic neuropathy in the pediatric population.